Brief: Hybrigenics' compound inhibits USP10 and shows activity in preclinical models of AML

Aton SA

09/10/2017 17:34

Oct 9 (Reuters) - HYBRIGENICS SA  ALHYG.PA : 
    * HYBRIGENICS' COMPOUND INHIBITS UBIQITIN-SPECIFIC PROTEASE 
10 (USP10) AND SHOWS ACTIVITY IN PRECLINICAL MODELS OF ACUTE 
MYELOID LEUKEMIA 
    * PUBLICATION IN "NATURE CHEMICAL BIOLOGY" IDENTIFIES USP10 
"AS A CRITICAL EFFECTOR ENZYME OF TUMOR GROWTH AND SURVIVAL IN 
SUBJECTS WITH FLT3-MUTATED AML 
    * PUBLICATION REPORTS "THE TOP HIT FROM OUR SCREEN, HBX 
19,818, LED TO STRIKING AND SELECTIVE ANTIPROLIFERATIVE EFFECTS 
AGAINST MUTANT-FLT3-POSITIVE AML CELLS" 
 
Source text: http://bit.ly/2xubfFL 
Further company coverage:  ALHYG.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))